Safety and Efficacy of Low-Dose Metronomic Cyclophosphamide Plus Vinorelbine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes.

May 2018 in “ Journal of Clinical Oncology ”

Shun Kudo

Studysummary This study observed that a combination of low-dose cyclophosphamide and vinorelbine appears safe and has promising antitumor activity in patients with metastatic breast cancer resistant to anthracyclines and taxanes, achieving a 44% objective response rate at 6 months with manageable toxicity levels.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on ascopubs.org →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

Gemcitabine in Combination with Vinorelbine in Elderly Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer

research Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer

9 citations , February 2012 in “Cancer Chemotherapy and Pharmacology”

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

research Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity

6 citations , June 1983 in “Cancer”

This study found that a chemotherapy regimen combining CMFVP and ACP treatments for unresectable metastatic breast cancer yielded a 66.7% overall response rate, with premenopausal women responding more favorably than postmenopausal women.

research Anlotinib or Bevacizumab Combined with Taxane/Capecitabine for the Second-Line or Subsequent Treatment of HER-2 Negative Metastatic Breast Cancer: A Retrospective Cohort Study

December 2025 in “Drug Design Development and Therapy”

This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.

research [Efficacy of combination chemotherapy with mitoxantrone, vincristine, prednisolone (MVP) for recurrence of breast cancer].

January 1995 in “PubMed”

This study found that a mitoxantrone, vincristine, and prednisolone regimen effectively treated recurrent breast cancer with a 70% response rate, though it was associated with significant myelosuppression.

research First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

22 citations , November 2005 in “BMC Cancer”

This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.